Drug Therapy

Gurjit Kaur, DO
Department of General Internal Medicine, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Lilian Gonsalves, MD
Department of Psychiatry and Psychology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Holly L. Thacker, MD
Department of General Internal Medicine, Department of Obstetrics and Gynecology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Address: Gurjit Kaur, DO, Department of General Internal Medicine, A91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Adminstration for the use under discussion.

Gurjit Kaur, DO
Department of General Internal Medicine, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Lilian Gonsalves, MD
Department of Psychiatry and Psychology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Holly L. Thacker, MD
Department of General Internal Medicine, Department of Obstetrics and Gynecology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Address: Gurjit Kaur, DO, Department of General Internal Medicine, A91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Adminstration for the use under discussion.

Gurjit Kaur, DO
Department of General Internal Medicine, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Lilian Gonsalves, MD
Department of Psychiatry and Psychology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Holly L. Thacker, MD
Department of General Internal Medicine, Department of Obstetrics and Gynecology, Women’s Health Center at The Gault Women’s Health and Breast Pavilion, The Cleveland Clinic Foundation

Address: Gurjit Kaur, DO, Department of General Internal Medicine, A91, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Adminstration for the use under discussion.

Bibi I. Hasnain, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Arshag D. Mooradian, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Address: Arshag D. Mooradian, MD, Division of Endocrinology, Saint Louis University, 1402 South Grand Boulevard, St. Louis, MO 63104; e-mail [email protected]

Bibi I. Hasnain, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Arshag D. Mooradian, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Address: Arshag D. Mooradian, MD, Division of Endocrinology, Saint Louis University, 1402 South Grand Boulevard, St. Louis, MO 63104; e-mail [email protected]

Bibi I. Hasnain, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Arshag D. Mooradian, MD
Division of Endocrinology, Diabetes, and Metabolism, Department of Internal Medicine, St. Louis University School of Medicine, St. Louis, MO

Address: Arshag D. Mooradian, MD, Division of Endocrinology, Saint Louis University, 1402 South Grand Boulevard, St. Louis, MO 63104; e-mail [email protected]

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Todd E. Rambasek, MD
Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical
Care Medicine, The Cleveland Clinic Foundation

David M. Lang, MD
Head, Section of Allergy and Immunology, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Mani S. Kavuru, MD
Director, Pulmonary Function Laboratory, Department of Pulmonary, Allergy, and Critical Care Medicine, The Cleveland Clinic Foundation

Address: Mani S. Kavuru, MD, Director, Pulmonary Function Laboratory, Department of Pulmonary and Critical Care Medicine, A72, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Lang has indicated that he has received honoraria from, carried out clinical research with, or served as a consultant for the Abbott, AstraZeneca, Aventis, Genentech/Novartis, GlaxoSmithKline, Merck, Pfizer, and Schering/Key corporations.

Dr. Kavuru has indicated that he has received grant or research support from and serves on the speakers’ bureaus of the Genentech/Novartis and GlaxoSmithKline corporations.

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Administration for the use under discussion.

Siwat Kiratiseavee, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Lawrence H. Brent, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Address: Lawrence H. Brent, MD, Einstein Arthritis Center, 5501 Old York Road, Korman 103, Philadelphia, PA 19141; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Aministration for the use under discussion.

Siwat Kiratiseavee, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Lawrence H. Brent, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Address: Lawrence H. Brent, MD, Einstein Arthritis Center, 5501 Old York Road, Korman 103, Philadelphia, PA 19141; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Aministration for the use under discussion.

Siwat Kiratiseavee, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Lawrence H. Brent, MD
Department of Medicine, Albert Einstein Medical Center, Philadelphia, PA

Address: Lawrence H. Brent, MD, Einstein Arthritis Center, 5501 Old York Road, Korman 103, Philadelphia, PA 19141; e-mail [email protected]

This paper discusses therapies that are experimental or are not approved by the US Food and Drug Aministration for the use under discussion.

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

John D. Clough, MD
Editor in Chief

William S. Harris, PhD
Lipid and Diabetes Research Center, Mid America Heart Institute of Saint Luke’s Hospital and Department of Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO

Address: William S. Harris, PhD, 4320 Wornall Road, Suite 128, Kansas City, MO 64111; e-mail [email protected]

The author has indicated that he is a major stock shareholder and cofounder of OmegaMetrix, a company involved in measuring blood levels of omega-3 fatty acids.

William S. Harris, PhD
Lipid and Diabetes Research Center, Mid America Heart Institute of Saint Luke’s Hospital and Department of Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO

Address: William S. Harris, PhD, 4320 Wornall Road, Suite 128, Kansas City, MO 64111; e-mail [email protected]

The author has indicated that he is a major stock shareholder and cofounder of OmegaMetrix, a company involved in measuring blood levels of omega-3 fatty acids.

William S. Harris, PhD
Lipid and Diabetes Research Center, Mid America Heart Institute of Saint Luke’s Hospital and Department of Medicine, University of Missouri-Kansas City School of Medicine, Kansas City, MO

Address: William S. Harris, PhD, 4320 Wornall Road, Suite 128, Kansas City, MO 64111; e-mail [email protected]

The author has indicated that he is a major stock shareholder and cofounder of OmegaMetrix, a company involved in measuring blood levels of omega-3 fatty acids.